Clinical Trials Directory

Trials / Conditions / Tick-borne Encephalitis

Tick-borne Encephalitis

22 registered clinical trials studyying Tick-borne Encephalitis — 2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingSerological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-b
NCT06859619
University Hospital, MontpellierN/A
UnknownPrimary TBE Vaccination for the Elderly
NCT04573205
Region Örebro CountyPhase 4
CompletedTick-borne Encephalitis Virus Research in Limousin
NCT05941546
University Hospital, Limoges—
UnknownPrevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of C
NCT05607394
University Hospital, Strasbourg, France—
CompletedStudy to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in H
NCT04648241
PfizerPhase 3
UnknownApplication of a TBE-Vaccine in Obese Persons
NCT04017052
Medical University of ViennaPhase 4
CompletedNew Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
NCT02318069
Sormland County Council, SwedenPhase 2 / Phase 3
RecruitingTick-borne Encephalitis and Borrelial Antibodies in Serum
NCT03956446
University Medical Centre LjubljanaN/A
UnknownTick-borne Encephalitis and Positive Borrelial Antibodies
NCT02463942
University Medical Centre LjubljanaN/A
CompletedHumoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
NCT01991067
Medical University of ViennaPhase 2
CompletedCervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
NCT01710189
University of SurreyPhase 4
CompletedStudy to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne
NCT01562444
GlaxoSmithKlinePhase 4
CompletedHumoral Response to Tick-borne Encephalitis Vaccine in Elderly
NCT01361776
Sormland County Council, SwedenPhase 2 / Phase 3
TerminatedVaccine Study for Tick-Borne Encephalitis Virus (TBEV)
NCT01031537
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
CompletedHumoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
NCT00804219
Medical University of ViennaPhase 4
UnknownEvaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With
NCT00890422
Elisabethinen HospitalPhase 2
CompletedTick-borne Encephalitis and Possible Borrelial Serology
NCT03958058
University Medical Centre Ljubljana—
CompletedSafety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
NCT00118924
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedInvestigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults
NCT00161785
PfizerPhase 4
CompletedSafety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
NCT00161863
PfizerPhase 3
CompletedDose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Hea
NCT00161772
PfizerPhase 2
CompletedDose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Hea
NCT00161798
PfizerPhase 2